05.12.2024 00:23:00
|
Why Janux Therapeutics Crushed the Market Today
News of an analyst's price-target hike plus a new round of capital-raising were the sparks that ignited Janux Therapeutics (NASDAQ: JANX) stock on Wednesday. The clinical-stage biotech's share price ended the day nearly 12% higher, and this was on a very good day for the exchange with the S&P 500 rising by 0.6%.Well before market open, Scotiabank pundit George Farmer aggressively raised his price target on Janux, cranking it nearly 50% higher to $62 per share. That doesn't necessarily make him a bull, though, as he maintained his recommendation of sector perform (hold, in other words). According to reports, Farmer wrote that the biotech company's current phase 1 trial of its JANX007 prostate cancer treatment is rather promising so far. That said, the analyst believes Janux hasn't yet honed a sharp competitive edge and isn't yet an attractive enough target for a pharmaceutical company to acquire it. Continue readingWeiter zum vollständigen Artikel bei MotleyFool
Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Janux Therapeutics Inc Registered Shsmehr Nachrichten
Keine Nachrichten verfügbar. |
Analysen zu Janux Therapeutics Inc Registered Shsmehr Analysen
Aktien in diesem Artikel
Janux Therapeutics Inc Registered Shs | 62,37 | -4,03% | |
The Market Limited Registered Shs | 0,08 | 0,00% |